

ASX Announcement

## Section 708A Cleansing Statement

**Melbourne, Australia; 9 January 2026:**

This notice is given by Lumos Diagnostics Holdings Limited Ltd (ASX: LDX) (**Company**) under Section 708A(5)(e) of the *Corporations Action 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

- (a) It has issued 5,000,000 Fully Paid Ordinary Shares (**Shares**) as the result of the exercise of 5,000,000 unquoted options held by Lind Global Fund II;
- (b) It has issued 228,863 Fully Paid Ordinary Shares (**Shares**) as the result of the cashless exercise of 272,467 unquoted options held by an employee of the Company;
- (c) the Shares referred to in paragraphs (a) and (b) above were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (d) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;
- (e) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (ii) section 674 of the Corporations Act as it applies to the Company; and
  - (iii) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act which is required to set out in this notice under Section 708A(6)(e) of the Corporations Act other than its half year financial report for the six months ended 31 December 2025 (**FY 2026 Half Year Report**) which is being prepared by the Company and will be released to the ASX on or before 27 February 2026. The Company confirms that the expected draft of the FY 2026 Half Year Report as at the date of this cleansing notice does not contain any excluded information within the meaning of sections 708A(7) and 708A(8) of the Act which is required to be disclosed under section 708A(6)(e) of the Corporations Act.

<ENDS>

This announcement has been approved by the Lumos Disclosure Committee.

### About Lumos Diagnostics

*Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.*

*For more information visit [lumosdiagnostics.com](http://lumosdiagnostics.com) or [febridx.com](http://febridx.com).*



**LUMOS**  
DIAGNOSTICS

### **Forward-Looking Statements**

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

### **Media Contacts:**

Haley Chartres – Australia  
H^CK Director  
[haley@hck.digital](mailto:haley@hck.digital)  
+61 (0) 423 139 163

### **Investor Contact:**

Jane Lowe  
Managing Director, IR Department  
[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)  
+61 411 117 774

### **Company Registered Office:**

Lumos Diagnostics Holdings Ltd  
Suite 2, Level 11, 385 Bourke Street  
Melbourne, VIC 3000  
[info@lumosdiagnostics.com](mailto:info@lumosdiagnostics.com)  
+61 3 9087 1598